Summary & Overview
HCPCS G2207: Reason for Not Administering Adjuvant Chemotherapy/HER2 Therapy
HCPCS Level II code G2207 documents clinical reasons why an adjuvant treatment course—specifically chemotherapy and HER2-targeted therapy—was not administered. The code matters nationally as a standardized mechanism to capture medically necessary omissions from planned adjuvant regimens due to factors such as poor performance status, organ dysfunction, cardiac contraindications, competing active cancers, death during initial treatment, or transfer of care. Accurate use of G2207 supports clinical documentation, quality measurement, and payer adjudication regarding exceptions to guideline-directed adjuvant therapy.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical intent and settings of use, an outline of common payers that cover adjudication and policy considerations, and an overview of what elements clinicians and billing teams typically document when reporting this code. The publication also summarizes common modifiers used with this service and notes where input data were not available. This content is intended for national audiences of clinicians, coding professionals, and policy analysts who need a clear reference on how G2207 is applied in oncology care delivery and administrative workflows.
Billing Code Overview
HCPCS Level II code G2207 documents the reason for not administering an adjuvant treatment course, including both chemotherapy and HER2-targeted therapy. Typical clinical reasons captured by this code include poor performance status (for example, ECOG 3-4 or Karnofsky ≤50), cardiac contraindications, insufficient renal or hepatic function, other active or secondary cancer diagnoses, other medical contraindications, death during the initial treatment course, or patient transfer during or after the initial treatment course.
Service Type: Adjuvant oncology treatment omission justification
Typical Site of Service: Hospital inpatient and outpatient oncology clinics, infusion centers, and cancer care units
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 67-year-old woman with stage II HER2-positive invasive ductal breast carcinoma completes surgery and initial staging. Adjuvant systemic therapy is planned but during pre-treatment assessment she is found to have a new reduced left ventricular ejection fraction of 35% on echocardiogram and baseline ECOG performance status of 3 with ongoing congestive symptoms. The oncology team documents that adjuvant chemotherapy and HER2-targeted therapy will not be administered due to cardiac contraindication and poor performance status. The clinical workflow includes multidisciplinary tumor board review, documentation of contraindications in the medical record, code G2207 billed to indicate the reason for not administering the adjuvant course, notification of the referring surgeon and primary care clinician, and counseling the patient regarding alternative supportive care and surveillance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when additional work/complexity in documentation is required to explain why adjuvant therapy was withheld beyond routine evaluation. |
23 | Unusual anesthesia | Rarely applicable; use only if anesthesia was required and unusually complex during an attempted procedure related to therapy decision-making. |
52 | Reduced services | Use when planned treatment course was partially delivered then discontinued due to contraindication or deterioration. |
53 | Discontinued procedure | Use when adjuvant therapy was initiated but stopped because of acute medical contraindication or death. |
54 | Surgical care only | Use when surgeon provides initial care and hands off systemic therapy decisions to oncology (rare for this code). |
55 | Postoperative management only | Use when postoperative follow-up documents decision not to start planned adjuvant therapy. |
56 | Preoperative management only | Use when pre-treatment evaluation determines contraindication prior to therapy initiation. |
62 | Two surgeons | Use when a second surgeon is required in complex perioperative decision-making impacting systemic therapy plans. |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery | Use when mid-level provider documents therapy contraindication under supervision. |
CO | Out-of-pocket payer responsibility | Use in Medicare crossover or vendor-specific contexts when patient is responsible for certain charges tied to documentation. |
CQ | Monoclonal antibody identification | Use when documenting use/withholding of HER2-targeted monoclonal antibody therapy in claims requiring this modifier. |
FY | Factor or drug not otherwise classified | Use when coding related drug administration events or exceptions on ancillary claims. |
QK | Medical direction of two, three, or four concurrent anesthesia cases | Rarely applicable; use only if concurrent anesthesia services occurred during related procedures. |
QX | Certified registered nurse anesthetist service with medical direction | Rarely applicable; use if CRNA provided anesthesia during a procedure tied to the therapy decision. |
QY | Medical direction of one certified registered nurse anesthetist | Rarely applicable; use if physician directed a CRNA during a peri-treatment procedure. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207Q00000X | Medical Oncology | Primary specialty documenting decisions about systemic adjuvant therapy. |
208D00000X | Hematology-Oncology | Specialists who commonly manage chemotherapy and targeted agents. |
207L00000X | Surgical Oncology | Surgeons involved in perioperative decision-making and documentation of adjuvant plans. |
208000000X | Internal Medicine | Hospitalists or internists who manage acute medical contraindications affecting therapy eligibility. |
363L00000X | Cardiology | Cardiologists who evaluate and document cardiac contraindications to HER2-targeted therapy. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
I50.9 | Heart failure, unspecified | Cardiac dysfunction is a common contraindication to HER2-targeted therapy and may justify use of G2207. |
I42.0 | Dilated cardiomyopathy | Objective cardiomyopathy often precludes administration of cardiotoxic chemotherapy or HER2-targeted agents. |
Z87.891 | Personal history of nicotine dependence | Comorbidity that can worsen cardiopulmonary status and influence therapy decisions. |
C50.919 | Malignant neoplasm of unspecified site of right female breast | Primary diagnosis for which adjuvant chemotherapy and HER2-targeted therapy would typically be planned. |
C50.912 | Malignant neoplasm of unspecified site of left female breast | Same clinical relevance for left-sided breast cancer. |
Z51.11 | Encounter for antineoplastic chemotherapy | Used when chemotherapy is administered; absence or discontinuation is documented with G2207 reasons. |
R53.1 | Weakness | Poor performance status may be coded as a reason to withhold adjuvant systemic therapy. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96413 | Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug | Commonly billed when adjuvant chemotherapy is administered; absence of this code may reflect use of G2207 when therapy is withheld. |
96417 | Chemotherapy administration, each additional hour | Billed when infusion exceeds initial hour; relevant when partial chemotherapy was given before discontinuation. |
96401 | Chemotherapy administration, subcutaneous or intramuscular; non-hormonal antineoplastic | Relevant for alternative routes if systemic therapy is considered but withheld. |
93306 | Echocardiography, transthoracic, real-time with image documentation, complete | Cardiac evaluation code often performed to assess eligibility for HER2-targeted therapy; abnormal result may lead to billing G2207 reason. |
99214 | Office or other outpatient visit for established patient, moderate complexity | Typical evaluation and documentation visit where contraindications to adjuvant therapy are assessed and G2207 justification recorded. |
36415 | Collection of venous blood by venipuncture | Laboratory testing for renal/hepatic function that informs decision to withhold adjuvant therapy. |